Citation Impact
Citing Papers
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease
2014
Gastric cancer
2016 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer
2006
EGFR Antagonists in Cancer Treatment
2008 Standout
Capecitabine: a novel agent for the treatment of solid tumors
2001
Pancreatic cancer
2004 Standout
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
2016 Standout
Clinical translation of angiogenesis inhibitors
2002 Standout
A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure
2011 Standout
Call to Develop a Standard Acquisition Charge Model for Kidney Paired Donation
2012 StandoutNobel
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
2000
Skin Toxic Effects of Polyethylene Glycol–Coated Liposomal Doxorubicin
2000
Cancer drug resistance: an evolving paradigm
2013 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
2003
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
2001 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
When to refer patients with chronic kidney disease for vascular access surgery: Should age be a consideration?
2007
The biology of VEGF and its receptors
2003 Standout
Colorectal cancer prevention and treatment
2000
Safety and antitumor activity of recombinant soluble Apo2 ligand
1999 Standout
Cancer genes and the pathways they control
2004 Standout
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
Minimizing Long-Term Tumor Burden: The Logic for Metronomic Chemotherapeutic Dosing and its Antiangiogenic Basis
2003
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
2007
Adjuvant Therapy for Colon Cancer 2005: New Options in the Twenty-First Century
2006
Endothelial cell effects of cytotoxics: balance between desired and unwanted effects
2004
Capecitabine: A review
2005
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment
2004 Standout
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin
2002
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer
1999
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial
2002 Standout
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
2002 Standout
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
2000 Standout
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
Toxicology of antisense therapeutics
2004
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Chronic Kidney Disease
2016 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
Hepatocellular carcinoma
2022 Standout
Tumorigenesis and the angiogenic switch
2003 Standout
Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies
2004
Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis
2010
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Angiogenesis Research: Guidelines for Translation to Clinical Application
2001
5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity
2007 StandoutNobel
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
2009 Standout
Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial
2003
Immunotherapy for Colorectal Cancer
2017
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
2001
Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review
2002
Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
2005
Combined Irinotecan and Oxaliplatin Plus Granulocyte Colony-Stimulating Factor in Patients With Advanced Fluoropyrimidine/Leucovorin-Pretreated Colorectal Cancer
1999
Prognostic value of glypican‑1 for patients with advanced pancreatic cancer following regional intra‑arterial chemotherapy
2018
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database
2018
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297
2002
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
2000
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
2007 Standout
Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation
2006 StandoutScience
Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer
1999
Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review
2008
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
2004
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Works of Elliot Levy being referenced
Navigation Systems for Ablation
2010
Managing Finances of Shipping Living Donor Kidneys for Donor Exchanges
2011
Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure
2002
Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
2011
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer.
1998
A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer.
2016
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.
1998